Form 4: SpringWorks Therapeutics Director Alan Fuhrman Receives Stock Options and Restricted Stock Units

Director Alan Fuhrman received stock options and restricted stock units from SpringWorks Therapeutics as part of the company's non-employee director compensation policy.

Summary

• On May 16, 2024, Alan Fuhrman, a director of SpringWorks Therapeutics, received 12,216 stock options with an exercise price of $44.77, which will vest on the earlier of May 16, 2025, or the next annual meeting of stockholders, contingent upon continued service.
• Fuhrman also received 4,095 restricted stock units (RSUs) that will vest on the earlier of May 16, 2025, or the next annual meeting of stockholders, subject to continued service.
• Following these transactions, Fuhrman directly owns 12,216 derivative securities and 14,667 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted equity.

Industry Context

This type of equity grant is a common practice for compensating non-employee directors in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a standard practice across the pharmaceutical and biotechnology industries.
• Companies like Pfizer, Amgen, and Gilead Sciences also provide similar equity grants to their non-employee directors as part of their overall compensation packages.
• The specific amount and terms of the grants can vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
• Employees are not directly impacted by this transaction.

Key Dates